



General AML

ASCO 2019 | Combination drugs in myeloid disorders

 **Zara Kassam** | Jun 05, 2019

Aref Al-Kali from the Mayo Clinic, Rochester, US, speaks with the AML Global Portal (AGP) at ASCO 2019, about combining drugs in myeloid disorders such as acute myeloid leukemia (AML). Aref Al-Kali stated that he was surprised that less than 10% of the audience at ASCO were combining venetoclax with hypomethylating agents or low dose cytarabine to treat patients with newly diagnosed AML who are unfit for intensive chemotherapy, despite the recent approval in the US. He also highlighted his concerns that some clinicians are using this strategy in the treatment of myelodysplastic syndrome (MDS), for which this combination, particularly venetoclax, has not yet been approved.

© 2019 Scientific Education Support Ltd. This PDF is provided for personal use only. For wider or commercial use, please seek permission from secretariat@scientificeducationsupport.com and attribute the source as: <https://amlglobalportal.com/medical-information/combination-drugs-in-myeloid-disorders>